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Purpose of the study
The association between abacavir exposure and cardiovas-
cular disease (CVD) in HIV-infected patients is currently
intensely debated. Recently, the D:A:D Study Group
described increased myocardial infarction risk in patients
with current/recent abacavir exposure, while repository
data from GlaxoSmithKline clinical trials failed to find
any association. Given the association between lym-
phocyte hyperactivation and CVD, and the major role of
T-cell hyperactivation in HIV/AIDS, the purpose of our
study was to investigate T-cell immunephenotype and
proinflammatory cytokines kinetics in HIV-infected
patients receiving abacavir-containing regimens.
Methods
Peripheral T-cell immunephenotype and proinflamma-
tory cytokines were evaluated in 11 HIV-infected patients
starting on an abacavir-containing HAART at baseline, 3
and 6 months. In particular, the following subpopula-
tions were quantified by flow cytometry: CD38+CD8+,
CD95+CD4+ and CD8+, CD127+CD8+. IL-6 and TNF-
alpha plasma levels were quantified by ELISA. During
abacavir treatment, all the patients underwent ultrasonog-
raphy of carotid and femoral vessels to evaluate intima-
media thickness (IMT).
Summary of results
Major results are shown in Table 1. We observed a signif-
icant rise in activated CD38+CD8+ (p < 0.01), and a
reduction in CD95+CD4+ and CD8+ (p < 0.01), suggest-
ing CD95 internalization on apoptosis-committed T-cells.
A non-significant contraction of central memory
CD127+CD8+ was shown, with no changes in plasma IL-
6 and TNF-alpha (p > 0.05). Interestingly, during abacavir
treatment all patients displayed carotid/femoral thicken-
ing involving at least one site.
Conclusion
While significantly reconstituting total CD4+, abacavir
resulted in significant expansion of activated/senescent/
pro-apoptotic T-cell subsets associated to vascular dam-
age. Analogously to other drug-toxicity models, a specific
interference of abacavir with purine signaling pathways
might be speculated, leading to impairment of lym-
phocyte activation. By suggesting T-lymphocye hyperacti-
vation as relevant in the pathogenesis of abacavir-related
CVD, these data, albeit preliminary, advocate thorough
assessment of possible immunologic biomarkers of
abacavir-related cardiovascular damage.
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Characteristic (n = 12) T0 T3 T6
Age, years 50 (33–67) NA NA
Current smoking, n 3/12 NA NA
Male/Female, n 9/3 NA NA
Current CD4 cells/μL 312 (91–1650) 348 (132–1664) 476 (234–1908)
Current CD4 % 25 (7–55) 24 (11–52) 26 (21–53)
CD38+CD8+ % 1 (0–47) 1 (1–4) 2 (1–3)
CD38+CD8+ n 21 (0–42) 23 (10–69) 33 (12–46)
CD95+CD4+ % 2 (1–9) 1 (0–4) 1 (1–1)
CD95+CD4+ n 26 (12–270) 21 (0–42) 19 (12–36)
CD95+CD8+ % 2 (1–10) 2 (1–6) 1 (1–2)
CD95+CD8+ n 31 (17–130) 30 (14–63) 22 (13–36)
CD127+CD8+ % 14 (9–24) 13 (5–28) 12 (5–25)
CD127+CD8+ n 269 (78–480) 208 (65–588) 218 (75–580)
TNF-alpha, pg/ml 2.7 (0.9–5.1) ND 2.6 (1.7–8.9)
IL-6, pg/ml 1.4 (0–6.5) ND 1.4 (0.5–3)
Total cholesterol, mg/dL 225 (154–301) 246 (159–339) 241 (186–366)
LDL cholesterol, mg/dL 133 (76–401) 50 (82–505) 53 (32–74)
Tryglicerides, mg/dL 136 (90–571) 169 (36–923) 227 (132–1137)
Homocysteinemia, mg/dL 12 (4.6–23.5) ND 11 (3.4–17.4)
IMT, mm right carotid ND ND 0.99 (0.79–1.49)
IMT, mm left carotid ND ND 0.99 (0.82–1.61)
IMT, mm right femoral ND ND 0.96 (0.83–1.24)
IMT, mm left femoral ND ND 1.01 (0.92–1.75)
Current HIV-RNA, Log10/mL 1,77 (1,77–4,3) 1,77 (1,77–2.4) 1,77 (1,77–3.9)Page 2 of 2
(page number not for citation purposes)
